To learn more or speak with a trial coordinator, please call 412-864-6600.
This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in subjects with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.
Principal Investigator: Jing Hou, MD, PhD
Evaluate the safety and efficacy of CC-486 and durvalumab in subjects with myelodysplastic syndromes who failed to achieve an objective response post iHMA treatment.
Principal Investigator: Robert Redner, MD